La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Outlook Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Outlook Therapeutics..

Outlook Therapeutics (NASDAQ:OTLK) Azioni, Catena delle Opzioni

OUTLOOK THERAPEUTICS INC

Outlook Therapeutics

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

OTLK

RCKT

Strategie per individuare titoli con potenziale di crescita basate su indicatori RSI e tendenze di mercato.

Opportunità di investimento: 3 aziende sottovalutate nel settore sanitario

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics Inc

Management

Press Releases

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Events

JTC Team Announces Participating Line Up for the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live

Outlook Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Health Care

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Earnings

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Outlook Therapeutics Requests Type A Meeting with FDA

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Penny Stocks

Outlook Therapeutics Provides Update on Type A Meeting with FDA

AKTX

AMIX

CNSP

MBRX

NUWE

NVNO

PALI

SNTI

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Annovis Bio

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

BioAtla

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Elutia

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Generation Bio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Liminatus Pharma, Inc. - Class A Common Stock

Liminatus Pharma

Lantern Pharma

LAVA Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

RenovoRx

Serina Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

Comments

Outlook Therapeutics

Outlook Therapeutics (OTLK) Opzioni

Outlook Therapeutics (NASDAQ:OTLK) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO